

Continued Consolidation in Healthcare and Insider Buying are positive signs for P3 Health Partners Inc. (NASDAQ: PIII)

Major Health Companies are Acquiring and Merging: CVS AET OSH; Could PIII be on the Radar?

HENDERSON, NEVADA, UNITED STATES, October 23, 2023 /EINPresswire.com/ -- Continued Consolidation in Healthcare and Insider Buying are positive signs for P3 Health Partners Inc. ([NASDAQ: PIII](https://www.nasdaq.com/symbol/piii))

Major Health Companies are Acquiring and Merging: CVS AET OSH; Could PIII be on the Radar?

For more information on PIII visit www.p3hp.org and follow PIII on @p3healthpartners and Facebook.com/p3healthpartners.



Health Management Network of Over 2,600 Affiliated Primary Care Providers Across the USA.

Currently Serving Over 100,000 Patients in 18 Counties Across Five States.

PIII Care Team Creates an Enhanced Patient Experience by Navigating, Coordinating and Integrating Care within the Healthcare System.

Significant Insider Buying of 270,000 PIII Shares by 10% Holder Chicago Pacific Founders UGP III, LLC in September.

Second Quarter Financial Results Showed Improvement Across All Key Metrics.

Capitated Revenue of \$325.6 Million, an Increase of 21.9% Compared to \$267.1 Million in Q2 of

the Prior Year.

Adjusted EBITDA of \$0.2 Million,
Compared to an Adjusted EBITDA Loss
of \$28.7 Million in the Q2 of the Prior
Year.

Gross Profit of \$26.8 Million, an
Improvement of \$24.8 Million
Compared to \$2.0 Million in the Q2 of
the Prior Year.


[P3 Health Partners, Inc. \(NASDAQ: PIII\)](#)

is a leading population health management company committed to transforming healthcare by improving the lives of both patients and providers. Founded and led by physicians, PIII has an expansive network of more than 2,600 affiliated primary care providers across the country. PIII local teams of health care professionals manage the care of thousands of patients in 18 counties across five states.



\$PIII Nasdaq PIII

Strong Markets, Relationships And Growth Trajectory



PIII supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, the PIII care team creates an enhanced patient experience by navigating, coordinating, and integrating the patient's care within the healthcare system.

“

We experienced approximately 1% medical cost trend for the quarter. That is a reflection of the effectiveness of P3's model and the increasing maturity of the membership on P3's platform.”

Dr. Sherif Abdou, CEO of PIII.

PIII has announced that it will participate at the upcoming Wells Fargo Healthcare Conference in Boston, Massachusetts. PIII Management will give a presentation on Thursday, September 7th, 2023, at 4:30 PM Eastern Time. A webcast of the live event will be available on the PIII Investor Relations website at ir.p3hp.org. A replay will be available shortly after the live event.

PIII will also participate in the Lake Street Best Ideas

Growth Conference in New York, New York on Thursday, September 14th, 2023.

Chicago Pacific Founders UGP III, LLC Buys 270,000 Shares of PIII

On September 13, 2023, Chicago Pacific Founders UGP III, LLC, a 10% owner of PIII made a significant insider purchase of 270,000 PIII common shares. This move is noteworthy as insider buying often signals confidence in the company's future prospects.

Chicago Pacific Founders UGP III, LLC is a private equity firm specializing in investments in the healthcare sector. The firm has a strong track record of identifying high-potential companies and helping them grow. Their investment in PIII further solidifies their belief in the company's potential.

Over the past year, the insider has purchased a total of 2,282,103 shares of PIII and sold 0 shares. This trend of consistent buying indicates a strong belief in the future growth potential of PIII. The insider transaction history for PIII shows a total of 13 insider buys over the past year, with no insider sells. This trend suggests that insiders at the company are bullish about its future prospects.

On the day of the insider's recent buy, shares of PIII were trading for \$2.54 apiece. This gives the stock a market cap of \$287.908 million. Despite the relatively small market cap, the consistent insider buying suggests that the company may be undervalued.

Insider buying is often seen as a positive signal by investors, as it suggests that those with the most insight into the company's operations see value in the stock. In the case of PIII the consistent buying by Chicago Pacific Founders UGP III, LLC suggests that the insider sees significant upside potential in the stock.

PIII Announces Second-Quarter 2023 Results

On August 7th PIII announced its financial results for the second quarter ended June 30, 2023.

"The results for the second quarter of 2023 show the power and trajectory of the P3 model. I'm delighted to say we had solid improvement across all key metrics. The strength we have seen in 2023 has given us the stability and momentum to drive our next phase of success in 2024, and beyond," said Dr. Sherif Abdou, CEO of PIII.

"We experienced approximately 1% medical cost trend for the quarter. That is a reflection of the effectiveness of P3's model and the increasing maturity of the membership on P3's platform. The

Foresight Acquisition Corp. Is Led By A World Class Management Team With Deep Operational And Investing Expertise



Greg Wasson
Chairman of the Board

Walgreens (NYSE:WAG) WASSON



Mark Thierer
Advisor

SXC Health Dentsply Sirona OPTUM Rx



Michael Balkin
Chief Executive Officer and Director

William Blair PHS



Kermik Crawford
Advisor

RITE AID SYCAMORE PARTNERS C.H. ROBINSON TransUnion

- Currently serves as President and Founder of his family office, Wasson Enterprise
- Former CEO and President of Walgreens from 2009 to 2014. Served Walgreens for 34 years, creating significant financial and shareholder value by initiating transformative mergers and investments, leading organizational change, assembling diverse leadership and establishing the company's position as an industry leader
- Invested and nurtured a portfolio of investments by adding value through his ability to catalyze relationships for businesses, channel partners, key hires, and strategic investors to build sustainable, high-growth businesses that do well by doing good
- Recognized throughout the drugstore and healthcare industry for transformational leadership, innovation, bold business decisions, and executing on strategic long-term visions

- Former Partner and Co-Manager of the William Blair Small Institutional portfolio and Small Cap Growth Fund
- Over 30 years of experience working with public companies in the small cap space
- Currently the Chairman of the Board of Performance Health Systems
- Former Partner at Magnetar Capital, LLC, a multi-strategy hedge fund
- Co-founded Cityview Associates, a real estate investment firm

- Lifelong leader in the healthcare space and known for his ability to transform companies and achieve financial and operational success
- Transformed a small pharmacy benefit management company (PBM) called SXC Health Solutions into one of America's largest and fastest growing players – then facilitated its \$12.8 billion sale to Optum
- Former CEO of OptumRx from 2015 to 2017
- Former CEO and Chairman of Catamaran from 2006 to 2015

- A pharmacy, health and wellness expert who has led transformational change and cost-saving programs in highly competitive consumer-focused businesses
- Previously served as an Operating Partner, Advisor and Consultant for Sycamore Partners, specializing in retail and consumer investments
- Former President and COO of Rite Aid Pharmacy

\$PIII Acquisition Corp.

value we deliver and demand for P3's model is rooted in our ability to bend the cost curve for our patients, providers, and payor clients," said Bill Bettermann, COO of P3.

Q2 Financial Results

Capitated revenue was \$325.6 million, an increase of 21.9% compared to \$267.1 million in the second quarter of the prior year

Net loss was \$27.6 million, compared to a net loss of \$903.1 million in the second quarter of the prior year. The second quarter of 2022 was negatively impacted by a goodwill impairment charge of \$851.5 million

Net loss PMPM was \$88 compared to a net loss PMPM of \$2,995 the second quarter of the prior year

Adjusted EBITDA(1) was \$0.2 million, compared to an Adjusted EBITDA loss of \$28.7 million in the second quarter of the prior year

Adjusted EBITDA PMPM(1) was roughly breakeven, compared to an Adjusted EBITDA loss PMPM of \$95 in the second quarter of the prior year

Gross profit was \$26.8 million, an improvement of \$24.8 million compared to \$2.0 million in the second quarter of the prior year

Gross profit PMPM was \$86, an improvement of \$79 compared to \$7 in the prior year

Medical margin(1) was \$50.5 million, an increase of 132.1% compared to \$21.8 million in the second quarter of the prior year

Medical margin PMPM(1) was \$161, an increase of 123.2% compared to a medical margin PMPM of \$72 in the prior year

First-Half 2023 Financial Results

Capitated revenue was \$624.3 million, an increase of 16.3% compared to \$536.8 million in the first half of the prior year

Net loss was \$80.0 million, compared to a net loss of \$963.9 million in the first half of the prior year. The first half of 2022 was negatively impacted by a goodwill impairment charge of \$851.5 million

Net loss PMPM was \$129 compared to a net loss PMPM of \$1,613 in the first half of the prior year

Adjusted EBITDA(1) loss was \$18.9 million, compared to an Adjusted EBITDA loss of \$47.6 million in the first half of the prior year

Adjusted EBITDA PMPM(1) loss was \$30, compared to an Adjusted EBITDA loss of \$80 PMPM in the first half of the prior year

Gross profit was \$43.3 million, an improvement of 345% compared to \$9.7 million in the first half of the prior year

Gross profit PMPM was \$70, an increase of 329% compared to \$16 in the first half of the prior year

Medical margin(1) was \$89.7 million, an increase of 92.6% compared to \$46.6 million in the first half of the prior year

Medical margin PMPM(1) was \$145, an increase of 85.9% compared to a medical margin PMPM of \$78 in the prior year

PIII management also conducted a conference call on August 7th. An archived recording of the webcast will be available on the Investor page of the PIII website for a period of 90 days following the conference call at this link: ir.p3hp.org.

For more detailed explanations of the above financial results review the PIII company filings at: <https://www.otcm Markets.com/stock/PIII/disclosure>

DISCLAIMER: CAP/FrontPageStocks/CorporateAds.com (CA) is a third-party publisher and news dissemination service provider. CAP/FPS/CA is NOT affiliated in any manner with any company mentioned herein. CAP/FPS/CA is a news dissemination solutions provider and is NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. CAP/FPS/CA's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. CAP/FPS/CA is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. CAP/FPS/CA has been compensated \$500 by a third party for dissemination of this article.

SOURCE: CorporateAds.com

Dr. Sherif Abdou, CEO
P3 Health Partners, Inc
+1 702-910-3950

[email us here](#)

Visit us on social media:

[Facebook](#)

[LinkedIn](#)

[Instagram](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/663470266>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.